NasdaqGS:MRNABiotechs
Moderna (MRNA) Loss Of US$2.8b Keeps Bearish Narratives In Focus
Moderna (MRNA) opened 2026 with Q1 results that continue the recent trend of revenue and losses sitting side by side, with trailing 12 month revenue at US$1.9 billion and a basic EPS loss of US$7.25 per share tied to a net loss of US$2.8 billion. Over recent quarters, the company has seen quarterly revenue move between US$108 million and US$1.9 billion with basic EPS ranging from a small profit of US$0.03 per share in Q3 2024 to losses of more than US$2.50 per share in several 2025 quarters,...